Johnson & Johnson (NYSE:JNJ) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $7.25-7.30 for the period, compared to the Thomson Reuters consensus estimate of $7.18. The company issued revenue guidance of $76.1-76.5 billion, compared to the consensus revenue estimate of $75.84 billion.

Several research firms have recently weighed in on JNJ. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a hold rating in a research note on Wednesday. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an outperform rating in a research note on Wednesday. Leerink Swann reissued an outperform rating and issued a $165.00 price target (up previously from $150.00) on shares of Johnson & Johnson in a research note on Wednesday. Vetr cut shares of Johnson & Johnson from a hold rating to a sell rating and set a $129.62 price target for the company. in a research note on Friday, October 13th. Finally, Alembic Global Advisors cut shares of Johnson & Johnson from a neutral rating to an underweight rating in a research note on Friday, July 21st. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $138.35.

Johnson & Johnson (JNJ) opened at 140.79 on Wednesday. The stock has a market capitalization of $377.88 billion, a P/E ratio of 23.82 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $141.12. The firm’s 50-day moving average is $132.57 and its 200 day moving average is $130.27.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.68 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Releases FY17 Earnings Guidance” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/johnson-johnson-jnj-releases-fy17-earnings-guidance/1638391.html.

Several large investors have recently modified their holdings of the business. Beach Investment Management LLC. increased its holdings in shares of Johnson & Johnson by 1,256.6% in the 2nd quarter. Beach Investment Management LLC. now owns 286,648 shares of the company’s stock worth $37,921,000 after acquiring an additional 265,518 shares during the period. Signature Financial Management Inc. increased its holdings in shares of Johnson & Johnson by 17.3% in the 2nd quarter. Signature Financial Management Inc. now owns 13,336 shares of the company’s stock worth $1,758,000 after acquiring an additional 1,967 shares during the period. United Asset Strategies Inc. increased its holdings in shares of Johnson & Johnson by 3.6% in the 2nd quarter. United Asset Strategies Inc. now owns 5,468 shares of the company’s stock worth $723,000 after acquiring an additional 192 shares during the period. Tortoise Investment Management LLC increased its holdings in shares of Johnson & Johnson by 3.3% in the 2nd quarter. Tortoise Investment Management LLC now owns 4,349 shares of the company’s stock worth $575,000 after acquiring an additional 139 shares during the period. Finally, Alpine Woods Capital Investors LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Alpine Woods Capital Investors LLC now owns 134,022 shares of the company’s stock worth $17,730,000 after acquiring an additional 2,117 shares during the period. 65.90% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.